Answers are grounded in this paper and cite their sources.
This case report highlights a rare occurrence of giant cell myocarditis following administration of the BNT162b2 mRNA vaccine.
Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context of myocarditis after mRNA vaccination we discuss this rare aetiology and the patient's treatment strategy in the light of current recommendations.
No takes yet. Share an insight, caveat, or question.
Hirsch et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: